Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 5, 2024
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
[ Fri, Jan 05th 2024
] - WOPRAI
Robert Burns Maintained (VIRX) at Strong Buy with Decreased Target to $4 on, Jan 5th, 2024
Robert Burns of HC Wainwright & Co., Maintained "Viracta Therapeutics, Inc." (VIRX) at Strong Buy with Decreased Target from $10 to $4 on, Jan 5th, 2024.
Robert has made no other calls on VIRX in the last 4 months.
There is 1 other peer that has a rating on VIRX. Out of the 1 peers that are also analyzing VIRX, 0 agree with Robert's Rating of Hold.
This is the rating of the analyst that currently disagrees with Robert
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $6 on, Friday, November 10th, 2023
